+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 2Years - 18Years
All Genders
ID06993636

Study of Rivaroxaban Treatment and Drug Levels in Chinese Children Aged 2 to 18 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease

Led by Children's Hospital of Fudan University · Updated on 2025-05-29

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an observational study to collect clinical data from children aged 2 to under 18 years who have giant coronary artery aneurysms after Kawasaki disease and are receiving rivaroxaban treatment. The study aims to analyze rivaroxaban plasma concentrations, anti-factor Xa activity levels, and genetic polymorphisms to support population pharmacokinetic and pharmacodynamic analysis. Participants will be treated with rivaroxaban as an anticoagulant combined with an antiplatelet drug for long-term blood clot prevention. The dosing regimen is optimized based on a model, and rivaroxaban plasma concentration and calibrated anti-FXa activity will be measured for clinical monitoring. Treatment and monitoring will continue for six months from the start of rivaroxaban therapy. During the study, scheduled blood samples will be collected from baseline to six months after starting rivaroxaban, including at the first hospitalization, to measure drug levels and anti-FXa activity. Researchers will also observe the occurrence of new coronary artery thrombosis and any major or clinically relevant bleeding events. The total participation duration covers this six-month monitoring period.

CONDITIONS

Brief Title

Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years

Research Team

F

Fang Liu, MD

G

Guangan Dai, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here